PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas

Neurosurgery

Volumn 43, Issue 5, 1998, Pages 1066-1073

  Soffietti, Riccardo ^a   Rudà, Roberta ^a   Bradac, Gianni Boris ^a   Schiffer, Davide ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Chemotherapy; Oligoastrocytoma; Oligodendroglioma; Recurrences

Indexed keywords

LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; FEMALE; HUMAN; INTRACRANIAL HYPERTENSION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGODENDROGLIOMA; PACLITAXEL; RADIOTHERAPY, ADJUVANT; TAXOIDS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VINBLASTINE;

EID: 0031756784     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199811000-00035     Document Type: Article

References (53)

1. Allison RR, Schulsinger A, Vongtama V, Barry T, Shin KH Radiation and chemotherapy improve outcome in oligodendroglioma. Int J Radial Oncol Biol Phys 37:399-103, 1997.
2. Balmaceda C, Hesdorfen C, Claudio AL, Espinal F, Fetell MR High-dose chemotherapy (HOC) for recurrent oligodendrogliomas. Presented at the First Scientific Meeting of the Society for Neuro-oncology, Santa Fe, New Mexico. November 8-10, 1996.
3. Bishop M, de la Monte SM Dual lineage of astrocytomas. Am J Pathol 135:517-527,1989.
4. Boiardi A, Silvani A, Pozzi A, Farinotti M, Fariselli L, Broggi G, Salmaggi A Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherpy. J Neurooncol 34:179-185,1997.
5. Brown M, Cairncross JG, Vick NA, Macdonald DR, Friedman HS, Dropcho EJ, Schold SC Differential response of recurrent oligodendroglioma versus astrocytoma to intravenous melphalan. Proceedings of the American Academy of Neurology. Neurology 40:397, 1990 (abstr).
6. Bruner JM Neuropathology of malignant gliomas. Semin Oncol 21:126-138, 1994.
7. Bullard DE, Rawlings CE HI, Philips B, Cox EB, Schold SC, Burger P Oligodendroglioma An analysis of the value of radiation therapy. Cancer 60:2179-2188, 1987.
8. Burger PC, Rawlings CE, Cox EB, McLendon RE, Schold SC, Bullard DE Clinicopathologic correlations in the oligodendroglioma. Cancer 59:1345-1352,1987.
9. Cairncross JG Response and control Lessons from oligodendroglioma. J Clin Oncol 13:2475, 1995 (letter).
10. Caimcross JG, Maedonald DR Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23:360-364,1988.
11. Cairncross JG, Maedonald DR Chemotherapy for oligodendroglioma Progress report. Arch Neurol 48:225-227, 1991.
12. Cairncross JG, Maedonald DR, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr, VVainman N, Eisenhauer E Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12:2013-2021, 1994.
13. Cairncross JG, Maedonald DR, Ramsay DA Aggressive oligodendroglioma A chemosensitive tumor. Neurosurgery 31:78-83,1992.
14. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A Cerebral oligodendroglioma Prognostic factors and life history. Neurosurgery 35:1018-1034,1994.
15. Cox DR Regression models and life tables. J R Stat Soc [B] 34:187-202,1972.
16. Daumas-Duport C, Tucker ML, Kolles H, Cervera P, Beuvon F, Varlet P, Udo N, Koziak M, Chodkiewicz JP Oligodendrogliomas Part II-A new grading system based on morphological and imaging criteria. J Neurooncol 34:61-78,1997.
17. Duffau H, Albuquerque L, Ameri A, Sanson M, Poisson M, Delattre JY Chemotherapy for newly diagnosed and recurrent anaplastic oligodendrogliomas and mixed gliomas An analysis of 42 cases-Proceedings of the American Academy of Neurology. Neurology 45:261, 1995 (abstr).
18. Glass J, Hochberg FH, Gruber L, Louis DN, Smith D, Rattner B The treatment of oligodendrogliomas and mixed oligodendrogliomaastrocytomas with PCV chemotherapy. J Neurosurg 76:741-745,1992.
19. Grant R, Liang BC, Page MA, Crane DL, Greenberg HS, Junck L Age influences chemotherapy response in astrocytomas. Neurology 45:929-933, 1995.
20. Grant R, Liang BC, Slattery J, Greenberg HS, Junck L Chemotherapy response criteria in malignant glioma. Neurology 48 1336-1340, 1997.
21. Kaplan EL, Meier P Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481,1958.
22. Kim L, Hochberg FH, Thornton AF, Harsh GR IV, Patel H, Finkelstein D, Louis DN Procarbazine, lomustine and vincristine (PCV) chemotherapy for Grade III and Grade IV oligoastrocytomas. J Neurosurg 85:602-607,1996.
23. Kirby S, Maedonald D, Fisher B, Caspar L, Cairncross G Preradiation chemotherapy for malignant glioma in adults. Can J Neurol Sei 23:123-127,1996.
24. Kleihues P, Burger PC, Scheithauer BW Histological Typing of Tumors of the Central Nervous System. Berlin, Springer-Verlag, 1993, ed 2, pp 11-51.
25. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestier ÖD, von Deimling A Shared allelic losses on chromosomes Ip and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54:91-95, 1995.
26. Kros JM, Pieterman H, van Eden CG, Avezaat CJ Oligodendroglioma The Rotterdam-Dijkzigt experience. Neurosurgery 34:959-966,1994.
27. Kros JM, Troost D, van Eden CG, van der Werf AJM, Uylings HB Oligodendroglioma A comparison between two grading systems. Cancer 61:2251-2259,1988.
28. Krouwer HG, van Duinen SG, Kamphorst W, van der Valk P, Algra A Oligoastrocytomas A clinicopathological study of 52 cases. J Neurooncol 33:223-238, 1997.
29. Kyritsis AP, Yung WKA, Bruner J, Gleason MJ, Levin VA The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 32:365-371, 1993.
30. Levin VA Controversies in the treatment of low-grade astrocytomas and oligodendrogliomas. Curr Opin Oncol 8:175-177,1996.
31. Lindegaard KF, Mork SJ, Eide GE, Halvorsen TB, Hatlevoll R, Solgaard T, Dahl O, Ganz J Statistical analysis of clinicopathological features, radiotherapy and survival in 170 cases of oligodendroglioma. ) Neurosurg 67:224-230,1987.
32. Macdonald DR Low-grade gliomas, mixed gliomas, and oligodendrogliomas. Semin Oncol 21:236-248, 1994.
33. Macdonald DR, Cascino T, Schold SC, Caimcross JG Response criteria for Phase II studies of malignant glioma. J Clin Oncol 8:1277-1280,1990.
34. Macdonald DR, Caspar LE, Cairncross JG Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27:573-574,1990.
35. Macdonald DR, O'Brien RA, Gilbert JJ, Cairncross JG Metastatic anaplastic oligodendroglioma. Neurology 39:1593-1596, 1989.
36. Mason WP, Krol GS, De Angelis LM Low-grade oligodendroglioma responds to chemotherapy. Neurology 46:203-207,1996.
37. Mork S, Lindegaard K-F, Halvorsen TB, Lehmann EH, Solgaard T, Hatlevoll R, Harvei S, Ganz J Oligodendroglioma Incidence and biological behaviour in a defined population. J Neurosurg 63:881-889,1985.
38. Nijjar TS, Simpson WJ, Gadalla R Oligodendroglioma The Princess Margaret Hospital experience (1958-1984). Cancer 71:4002-4006,1993.
39. Paleologos NA, Vick NA, Kachoris JP Chemotherapy for low-grade oligodendrogliomas? Proceedings of the American Neurological Association. Ann Neurol 36:294-295, 1994 (abstr).
40. Peterson K, Cairncross GJ Oligodendroglioma. Cancer Invest 14:243-251,1996.
41. Peterson K, Paleologos NA, Forsyth P, Macdonald DR, Cairncross JG Salvage chemotherapy for oligodendrciglioma. J Neurosurg 85:597-601,1996.
42. Rajan B, Ross G, Lim CC, Ashley S, Goode D, Traish D, Brada M Survival in patients with recurrent glioma as a measure of treatment efficacy Prognostic factors following nitrosurea chemotherapy. Eur J Cancer 30A:1809-1815,1994.
43. Russell DS, Rubinstein LJ Pathology of Tumors of the Nervous System. Baltimore, Williams & Wilkins, 1989, ed 5.
44. Saarinen UM, Pihko H, Mäkipernaa A High-dose thiotepa with autologous bone marrow rescue in recurrent malignant oligodendroglioma A case report. J Neurooncol 9:57-61,1990.
45. Schiffer D, Giordana MT, Mauro A, Soffietti R Oligodendroglial tumors, in Brain Tumors Biology, Pathology and Clinical References. Berlin, Springer-Verlag, 1997, ed 2, pp 214-227.
46. Shaw EG, Scheithauer BW, O'Fallon JR, Davis DH Mixed oligoastrocytomas A survival and prognostic factor analysis. Neurosurgery 34:577-582,1994.
47. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH Oligodendrogliomas The Majo Clinic experience. J Neurosurg 76:428-434,1992.
48. Shimizu KT, Tran LM, Mark RJ, Selch MT Management of oligodendrogliomas. Radiology 186:569-572,1993.
49. Smith MT, Ludwig CL, Godfrey AD, Armbrustmacher VW; Grading of oligodendrogliomas. Cancer 52:2107-2114, 1983.
50. Soffietli R, Chiö A, Mocellini C, Rudà R, Vigliani MC, Schiffer D Response of oligodendroglial tumors to PCV chemotherapy. Proceedings of the American Academy of Neurology. Neurology 44:309, 1994 (abstr).
51. Stewart DJ, Dahrouge S, Soltyo K A Phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults. J Neurooncol 23 249-252,1995.
52. Van den Bent MJ, Kros JM, Schellens JHM, Krouwer HGJ, Zonneberg BA, Heimans }], von Groeningen CJ, Boogerd W, Tijssen CC, Twijnstra A PCV-chemotherapy in recurrent oligodendroglioma Factors of prognostic significance. Proceedings of the American Academy of Neurology. Neurology 46:180,1996 (abstr).
53. VVallner KE, Gonzales M, Sheline GE Treatment of oligodendrogliomas with or without postoperative irradiation. J Neurosurg 68:684-688, 1988.